Niki BioSolutions, Inc. (NIKI) Income Statement
NIKI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsNIKI revenue and net income
NIKI profit margins
NIKI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
NIKI quarterly EPS vs estimates
NIKI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $431,378 | $1.3M | $1.5M | $911,509 | $535,166 | $383,450 | $0 |
| Cost of revenue | $0 | $255,046 | $420,812 | $1.2M | $1.5M | $1.0M | $794,545 | $318,011 | $58,903 |
| Gross profit | $0 | −$255,000 | $10,566 | $80,065 | $81,854 | −$104,000 | −$259,000 | $65,439 | −$58,903 |
| Research & development | $352,879 | $1.9M | $5.2M | $9.2M | $10.9M | $11.6M | $6.9M | $3.1M | $2.5M |
| Sales, general & admin | $1.6M | $1.5M | $4.4M | $8.0M | $8.0M | $7.7M | $10.8M | $6.7M | — |
| Total operating expenses | $1.8M | $3.5M | $10.6M | $17.3M | $19.3M | $20.2M | −$259,000 | $10.4M | $5.6M |
| Operating income | −$1.8M | −$3.8M | −$10.6M | −$17.5M | −$19.2M | −$19.9M | −$18.2M | −$10.3M | −$5.7M |
| Interest income | — | — | — | $146,588 | — | — | — | — | — |
| Interest expense | $95,713 | $146,924 | $121,145 | — | $93,601 | $243,628 | $3.7M | $4.5M | — |
| Income before taxes | −$1.4M | −$4.2M | −$4.3M | −$11.5M | −$27.1M | $4.9M | −$20.1M | −$15.1M | −$2.6M |
| Income taxes | — | — | — | — | — | — | — | — | −$14,048 |
| Net income | −$1.4M | −$4.3M | −$2.8M | −$9.8M | −$25.0M | $7.1M | −$18.7M | −$14.8M | −$2.5M |
| EBITDA | −$1.8M | −$3.7M | −$9.2M | −$10.0M | −$25.8M | $6.5M | −$15.1M | −$10.0M | −$2.5M |
| EPS (diluted) | −$1.24 | −$67.85 | −$73.38 | −$274.51 | −$730.26 | $235.57 | −$644.38 | −$511.45 | — |
| Gross margin | — | — | 2.4% | 6.2% | 5.3% | −11.4% | −48.4% | 17.1% | — |
| Operating margin | — | — | −2,457.5% | −1,351.0% | −1,245.6% | −2,182.6% | −3,400.4% | −2,693.4% | — |
| Net margin | — | — | −654.9% | −756.2% | −1,624.4% | 775.3% | −3,491.8% | −3,868.0% | — |
| Dec '25 | Sep '25 | Dec '24 | Sep '24 | Mar '24 | Sep '23 | Mar '23 | Jun '22 | Mar '22 | Jun '21 | Mar '21 | Jun '20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $431,378 | $768,427 | $527,462 | $903,994 | $637,784 | $584,236 | $327,273 |
| Cost of revenue | — | — | — | $255,046 | $454,606 | $1.1M | $1.3M | $1.1M | $1.4M | $1.2M | $1.2M | $1.1M |
| Gross profit | — | — | — | −$255,000 | −$455,000 | −$665,000 | −$542,000 | −$585,000 | −$522,000 | −$589,000 | −$627,000 | −$812,000 |
| Research & development | $91,711 | $241,793 | $284,466 | $1.8M | $2.6M | $2.6M | $4.1M | $4.0M | $4.9M | $5.0M | $6.8M | $3.8M |
| Sales, general & admin | $617,198 | $411,904 | $445,325 | — | — | — | $6.3M | — | $6.4M | — | $6.7M | $3.4M |
| Total operating expenses | $825,131 | $589,631 | −$558,599 | $2.5M | $3.5M | $5.9M | $8.5M | $7.9M | $9.2M | $8.9M | $11.0M | $7.5M |
| Operating income | −$825,131 | −$402,766 | $558,599 | −$2.9M | −$4.0M | −$6.5M | −$9.1M | −$8.5M | −$9.7M | −$9.5M | −$11.6M | −$8.3M |
| Interest expense | — | $26,964 | — | $68,462 | $27,667 | $93,478 | $3,146 | — | $3.70B | $126,101 | $3.70B | $1.6M |
| Income before taxes | −$310,540 | −$616,595 | −$770,347 | −$2.7M | $2.3M | −$6.6M | −$8.8M | −$2.7M | −$10.0M | −$17.1M | $11.9M | −$7.0M |
| Net income | −$307,495 | −$613,995 | −$919,900 | −$2.6M | $2.7M | −$5.5M | −$7.9M | −$1.9M | −$9.0M | −$16.1M | $13.3M | −$6.2M |
| EBITDA | −$825,131 | −$589,631 | $275,924 | −$2.3M | $2.7M | −$5.8M | −$8.2M | −$2.1M | −$9.4M | −$16.4M | $12.6M | −$6.1M |
| EPS (diluted) | −$0.38 | −$0.86 | — | — | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | −154.2% | −70.5% | −110.9% | −57.7% | −92.4% | −107.3% | −248.1% |
| Operating margin | — | — | — | — | — | −1,515.8% | −1,178.8% | −1,602.4% | −1,074.5% | −1,488.6% | −1,986.5% | −2,532.7% |
| Net margin | — | — | — | — | — | −1,272.0% | −1,029.9% | −357.4% | −991.9% | −2,521.4% | 2,271.5% | −1,896.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in NIKI's financial statements (latest annual report filed March 27, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
NIKI financial results
Niki BioSolutions reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $1.4 million. Diluted earnings per share came to −$1.24.
See the NIKI stock overview for the latest quote and news, or the NIKI chart for price history and technical indicators.
NIKI income statement FAQ
Does Niki BioSolutions have revenue?
Niki BioSolutions reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Niki BioSolutions profitable?
No. Niki BioSolutions reported a net loss of $1.4 million in fiscal 2025.
How much does Niki BioSolutions spend on research and development?
Niki BioSolutions spent $0.4 million on research and development in fiscal 2025.
What are Niki BioSolutions's earnings per share?
Niki BioSolutions earned $-1.24 per diluted share in fiscal 2025, compared with $-67.85 a year earlier.
When does Niki BioSolutions's fiscal year end?
Niki BioSolutions's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 27, 2026.